Skip to content
lung-fibrosis-lpwebpage-banner-image

Ready-2-Go

Lung Fibrosis Assay Services

Commonly-used fibrosis assays are often either too low throughput or are poorly predictive of downstream success. Our R2G Lung Fibrosis Assay Service can help you find better candidates in early drug discovery.

Ready-2-Go

Lung Fibrosis Assay Services

Commonly-used fibrosis assays are often either too low throughput or are poorly predictive of downstream success. Our R2G Lung Fibrosis Assay Service can help you find better candidates in early drug discovery.

Key Features & Benefits

  • Control fibrosis induction in 2D model. Cell culture protocols limit stress-fiber formation.

  • Pathologically relevant readout. ɑ-SMA in stress fibers are measured.

  • High-content analysis. Cell morphologies and other phenotypes are measured in addition to ɑ-SMA.

  • Uses a physiologically relevant model. Primary normal human lung fibroblasts (NHLF) cells.

  • R2G assay services are a starting point. Transition to more complex, bespoke assay services with the same service provider.

Key Features & Benefits

  • Control fibrosis induction in 2D model. Cell culture protocols limit stress-fiber formation.

  • Pathologically relevant readout. ɑ-SMA in stress fibers are measured.

  • High-content analysis. Cell morphologies and other phenotypes are measured in addition to ɑ-SMA.

  • Uses a physiologically relevant model. Primary normal human lung fibroblasts (NHLF) cells.

  • R2G assay services are a starting point. Transition to more complex, bespoke assay services with the same service provider.

Assays Designed with Your Goals in Mind

Fibrosis is a pathological state that arises from abnormal tissue repair, whereby connective tissue replaces healthy tissue to an extent that disrupts normal functioning of the organ. It is characterized by the accumulation of proteins in the extracellular matrix, which results from prolonged activation of myofibroblasts following various types of severe or repetitive tissue damage. Prolonged myofibroblast activation induces the formation of alpha smooth muscle actin (α-SMA)-containing stress fibers, a common marker in fibrosis assays including our R2G Lung Fibrosis Assay Service.

The Challenge

Most current fibrosis assays are not well suited for early stages of drug discovery. Simpler models of fibrosis often fail because standard cell-culture procedures tend to induce fibrosis-like phenotypes, making it difficult to distinguish between healthy and diseased states. In contrast, while 3D models of fibrosis can distinguish the two phenotypes, they are not amenable to high throughput screening, which limits the potential and efficiency of drug-candidate identification.

Our Solution

Our Ready-2-Go (R2G) Lung Fibrosis Assay Service uses primary, normal human fibroblasts (NHLF) cells cultured using a protocol that limits basal induction of fibrosis (which is often observed with routine, cell-culture procedures) to generate a 2D model of fibrosis. This not only allows for enhanced control of fibrotic induction, but also affords a format amenable to higher-throughput therapeutics profiling.

How It Works

process-timeline

Primary normal human lung fibroblasts (NHLF) are cultured using a specialized protocol that limits induction of fibrosis prior to running the experimental procedure. Cells are seeded into 384-well plates and compounds are added to the cells for 30 minutes before inducing fibrosis with TFG-β. After 48 hours and 72 hours of TGF-β stimulation, cells are fixed and stained (see below) for imaging and analysis.

lung-fibrosis-rep-images
lung-fibrosis-bar-graph-total-phalloidin-intensity

The representative images of NHLF cells shown above were taken following 48-hour exposure to either vehicle (PBS) (left), TGF-β (middle), or TGF-β + inhibitor ALK5i (a.k.a. Galunisertib) (right). The images show a visible increase in the levels of actin filaments and α-SMA-containing fibers increased with TGF-β treatment, a phenotype not observed when cells were pre-treated with the inhibitor ALK5i. This observation was quantified by measuring the total phalloidin intensity at different concentrations of TGF-β, with and without ALK5i inhibitor present, and is shown on the graph on the right.

Assay Service Details

  Ready-2-Go Lung Fibrosis Bespoke Assay Services
Cells NHLF (Lonza, CC-2512) If you would like to expand the service offering beyond R2G shown on left, please contact us.
Markers Hoechst (nuclei), Phalloidin (F-actin), and α-SMA antibody  
Dosing 6 doses of your test article  
Positive Control* TGF-β  
Negative Controls* 1D-11; Alk5i (Galunisertib)  
Format 384-well  
Replicates Triplicates (at a minimum)  
Assay Readouts Phalloidin intensity, nuclear count, α-SMA intensity in phalloidin-positive fibers, Cell Morphology (cell area, length-to-width ratio)  

*Vehicle and untreated controls also included.

TOUCH

Mission

Mission

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. Lorem ipsum dolor sit amet, consetetur sadipscing elitr. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor.
TOUCH

Vision

Vision

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. Lorem ipsum dolor sit amet, consetetur sadipscing elitr. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor.
TOUCH

Manifesto

Manifesto

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. Lorem ipsum dolor sit amet, consetetur sadipscing elitr. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor.

OUR BUSINESS PARTNERS

We love the collaboration with our business partners & vendors and therefore proudly present them here with the client logo module.

OUR OFFICE

Headquarters, Munich
Pelikanstrasse 2
80333, Munich, DE
POWER TIMELINE

OUR COMPANY HISTORY

  • 2015 - COMPANY START

    Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. 
  • 2016 - FIRST MILESTONE

    Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. 
  • 2018 - SECOND MILESTONE

    Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. 
  • 2020 - TODAY

    Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. 
GET IN TOUCH

LET'S HAVE A CHAT AND TALK ABOUT YOU